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A B S T R A C T
Background: The generalizability of findings from studies exploring the efficacy of psychotherapy and anti-
depressants has been called into question in part because studies exclude many patients. Despite this, the fre-
quency with which psychotherapy and antidepressant studies use specific inclusion and exclusion criteria has
never been compared. We explored the exclusion criteria used in psychotherapy and pharmacotherapy studies
from 1995 to 2014.
Method: Systematic literature searches were conducted in PubMed, Medline, PsycINFO, and Embase of pub-
lished randomized controlled trials (RCTs) of the treatment of major depressive disorder (MDD) in adults with
either antidepressants (vs. placebos) or psychotherapy (vs. placebos, treatments as usual, or other controls).
Results: Most psychotherapy (81%) and antidepressant (100%) trials excluded patients with milder symptoms as
well as patients with elevated suicidal risk (56–75%), psychotic symptoms (84–88%), or substance misuse
(75–81%). Psychotherapy studies were less likely to exclude patients on the basis of brief episode duration (0%
vs. 48%) and co-morbid Axis I disorders (6% vs. 27%). However, psychotherapy studies excluded patients with
more severe symptoms more frequently (38%) than antidepressant studies (8%).
Conclusions: Overall, psychotherapy studies appear somewhat more inclusive than antidepressant studies. On
average, antidepressant studies appear to target patients with more chronic and severe, as well as more purely
depressive presentations.
1. Introduction
The generalizability of treatment studies in mental health has been a
topic of much debate. More than 20 years ago, Seligman (1995) pointed
out that biases in the selection of patient samples in psychotherapy
trials, specifically the exclusion of co-morbidities and subclinical pre-
sentations, represent a serious threat to the generalizability and ap-
plicability of findings from psychotherapy research. Zimmerman et al.
(2002) made similar observations regarding the state of the research on
medications for depression and provided evidence that most patients
seen in outpatient practice were ineligible for a prototypical anti-
depressant efficacy trial. The issue of the representativeness of parti-
cipants from treatment trials is of special importance in the study of
treatments of major depression because this disorder is characterized by
a high degree of heterogeneity in presentation, co-morbid features, and
prognosis (Kessler et al., 2016; Lorenzo-Luaces, 2015; Parker, 2005). In
an early study addressing this issue, Westen and Morrison (2001) re-
ported that most (68%) patients with depression were excluded from a
typical psychotherapy study. Summarily reviewing the literature on
psychotherapies for depression, these authors stated that:
“the prototypical study of treatment for depression excluded pa-
tients for suicidality or comorbid substance use disorders. Several
studies also excluded patients who had one or more of the following:
GAD, panic disorder, antisocial personality disorder, severe obses-
sional symptoms, schizotypal features, or significant physical pro-
blems. Several excluded patients if these comorbid conditions were
considered primary but did not define how that determination was
made (or report reliability of that determination). The majority of
studies required a diagnosis of major depressive disorder for inclu-
sion.” (p. 886)
Although exclusion rates appear to be high, as Wiltsey-Stirman et al.
(2003) note, many different criteria are used for exclusion and not all
are threats to generalizability. For example, a patient may be excluded
from an outpatient trial testing the efficacy of a medication for de-
pression if it is deemed that they require a higher level of care (e.g.,
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hospitalization) than what is being provided. Such a decision comports
with the “real world” delivery of mental health care. It bolsters, and
does not threaten, external validity. Thus, it is necessary to consider the
specific reasons why patients are excluded from treatment trials before
assuming that the exclusions are a threat to the external validity of
studies.
Recently, Zimmerman and colleagues reviewed the frequency with
which inclusion and exclusion criteria are applied in studies exploring
the efficacy of antidepressants (Zimmerman et al., 2015, 2016a, 2016b,
2016c). According to these authors, the most commonly used exclusion
criteria were: minimum symptom severity (required by 100% of the
trials), a diagnosis of a psychotic disorder or current psychotic features
(84%), substance abuse or dependence (81%), and significant suicid-
ality (75%). Similar findings were produced by van der Lem et al.
(2012), who reported that a minimum symptom severity (80%), a di-
agnosis of a psychotic disorder or current psychotic features (90%),
substance abuse or dependence (85%), and significant suicidality (40%)
were frequently used as exclusion criteria for psychotherapy studies.
Huhn et al. (2014) conjectured that psychotherapy trials, by virtue
of requiring patients who can actively contribute to therapy have more
“well-selected” samples, which are less generalizable than the samples
in pharmacotherapy studies. Although a cursory comparison of the
studies by van der Lem et al. (2012) and Zimmerman et al. (2015,
2016a, 2016b, 2016c) argues against this conclusion, it is not possible
to compare these figures because the authors explored different years of
publication and applied different exclusionary criteria. A prior study
explored the application of prototypical inclusion criteria in studies for
adult depression but without actually studying how often these criteria
were employed or comparing them in antidepressant vs. psychotherapy
trials (Blanco et al., 2008). To address this gap in the literature, we
aimed to compare the frequency with which exclusion criteria are used
in trials of antidepressants versus psychotherapy focusing on adults in
contemporary trials published between 1995 and 2014. Existing data
suggests that psychotherapy studies may be somewhat more general-
izable than pharmacotherapy studies for borderline personality
(Hoertel et al., 2015), social anxiety (Hoertel et al., 2014), and post-
traumatic stress disorder (Franco et al., 2016) though not generalized
anxiety disorder (Hoertel et al., 2012). In adolescent depression, the
exclusion criteria used in psychotherapy studies tends to exclude fewer
adolescents than the exclusion criteria used in pharmacotherapy studies
(Blanco et al., 2017). Given these data, we hypothesized that psy-
chotherapy studies would be overall less likely to use psychiatric ex-
clusion criteria than antidepressant studies.
2. Methods
Randomized controlled trials (RCTs) exploring the efficacy of psy-
chotherapy or antidepressants were obtained by referencing recent re-
views of the treatment of adult depression (Cuijpers et al., 2008b;
Zimmerman et al., 2015) which employed searches in PubMed, Embase,
and PsychINFO, and identified individual studies by reviewing meta-
analyses and individual journals.
There are systematic differences between antidepressant and psy-
chotherapy studies regarding the type of controls employed in RCTs
(Huhn et al., 2014). Virtually all pharmacotherapy studies use a pill
placebo whereas the efficacy of psychotherapy is tested with a more
diverse mix of controls including: a waiting list (WL), treatment as usual
(TAU), pill placebos, and other conditions (e.g., relaxation) that are
intended to control for non-specific effects (e.g., attention). Thus, we
did not limit our search to the few psychotherapy studies that used a
pill placebo and instead included RCTs that used WL, TAU, or other
non-therapeutic controls (e.g., psychoeducation). Our search was
broadly for psychotherapeutic interventions, irrespective of treatment
orientation, in which a therapist delivered material intended to be
therapeutic either face to face or by telephone. We excluded guided
self-help or internet-based therapy. We included in our search the major
therapeutic orientations (e.g., cognitive-behavioral therapy (CBT), be-
havioral activation (BA), psychodynamic therapy), as well as suppor-
tive therapy if it was compared to a control. We required psychotherapy
studies to be compared to control conditions so the set of studies would
be more comparable to antidepressant-placebo studies (i.e., instead of
comparisons of two antidepressants).
Our review was limited to studies of adults with a diagnosis of major
depressive disorder not simply major depressive episodes (which could
include bipolar depression). We examined acute treatment outcome
studies and excluded studies on maintenance treatment and relapse
prevention. We excluded trials that focused on co-morbidities, psy-
chiatric or general medical, as they are, by definition less inclusive. For
a similar reason, we did not include trials focused on subtypes of de-
pression (e.g., treatment-refractory, chronic, psychotic, atypical, or
melancholic). However, we included studies that sampled patients
based on demographic features (e.g., low-income, minority). Trials
based on inpatients or patients with specific symptoms were also ex-
cluded.
The antidepressant efficacy trials reviewed by Zimmerman et al.
(2015) were the product of a search through PubMed, Embase, and
PsychINFO using the search terms depression or depressive and placebo
along with reviews of meta-analyses and the table of contents of 49
journals in which were antidepressant trials are typically published.
This process resulted in 170 articles comparing an antidepressant to a
placebo. The psychotherapy trials reviewed by Cuijpers et al. (2008b)
were the product of a similar search though PubMed, Embase, Psy-
cINFO, and the Cochrane Central Register of Controlled Trials using the
search terms depression or depressive and various search terms for treat-
ments (e.g., clinical trial, cognitive-behavioral therapy) along with reviews
of meta-analyses. The search process has been described in detail
elsewhere and produced a database of comparative psychotherapy
outcome studies (Cuijpers et al., 2008b) available in http://www.
evidencebasedpsychotherapies.org. The database is updated through
2014 with the search process described by Cuijpers et al., 2008b. The
application of our exclusion criteria to this database resulted in 16
studies comparing a psychotherapy to at least one control condition
(WL, TAU, or other controls). The list of psychotherapy and anti-
depressant studies can be found in the Appendix.
One of the authors (MZ) reviewed all of the articles and a second
author served as an independent second reviewer. Each reviewer read
each article and completed a pre-specified information extraction form
listing common psychiatric inclusion and exclusion criteria used in
treatment studies. The reviewers compared the results of their data
abstraction, and resolved discrepancies. Descriptive analyses summar-
izing the specific features of the psychotherapy trials are presented.
Because a prior study suggested that year of publication was associated
with the use of exclusion criteria (Zimmerman et al., 2015), we first
compared the year of publication for psychotherapy vs. pharma-
cotherapy studies using a t-test. To compare the differences between
antidepressant and psychotherapy studies in the number of studies
endorsing specific inclusion criteria we used a chi-square test, or Fish-
er's exact test when any cell in the 2× 2 table was expected to have a
frequency lower than 5.
3. Results
Sixteen randomized controlled trials comparing a psychotherapy to
a control were analyzed. Most of the psychotherapy studies (81%) ex-
plored the efficacy of one of the cognitive-behavioral therapies (CBTs).
The other studies explored the efficacy of interpersonal psychotherapy
(n= 2) or psychodynamic therapy (n=1). Most studies used TAU
(56%, n= 9) as the control condition. The remaining studies used
placebos (n=4) or waiting lists (n= 2), and a single study used re-
laxation training as a control condition (Murphy et al., 1995). There
were no statistically significant differences (t(187) = 1.22, p=0.23) in
the average year of publications of psychotherapy (M =2005.13, SD
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=6.16) vs. antidepressant (M =2007.04, SD =6.56) trials.
Table 1 summarizes the clinical/psychiatric exclusion criteria used
in the RCTs exploring the efficacy of psychotherapies or anti-
depressants. Four criteria were used in at least half of the psy-
chotherapy studies: psychotic disorder or current psychotic symptoms
(81%), substance abuse or dependence (88%), minimum symptom se-
verity on a depression scale (81%), and significant suicidal ideation
(56%). As has been noted of the antidepressant treatment studies, the
definition of some exclusion criteria varied between studies. For ex-
ample, although most of the studies used symptom severity as an ex-
clusion criterion, there was variability in what symptom measure was
used to quantify severity and what cut-off was used. Similarly, many
studies excluded patients with current or recent substance use disorders
but there was substantial variability in whether patients were excluded
due heavy substance use, meeting criteria for abuse, or dependence.
Virtually all the exclusion criteria we coded were used less frequently in
the psychotherapy trials, though not all these differences were statis-
tically significant. The largest observed difference was that around half
(48%) of antidepressant studies imposed a minimum episode duration
that was longer than the DSM requirement of 2 weeks but none (0%) of
the psychotherapy studies explicitly used this exclusion criterion
(p < 0.001). Two psychotherapy studies required participants to meet
the minimum symptom severity in two assessments separated by a two-
week period, thus technically imposing minimum depression duration
of 4 weeks (i.e., the initial 2 weeks required by the diagnosis of major
depression plus the two weeks between the assessment). Re-coding
these studies as requiring a minimum duration did not change the re-
sult; antidepressants studies were still more likely to use a minimum
episode duration criterion (48% vs. 13%, p < 0.0075).
Only one psychotherapy efficacy trial (6%) excluded participants on
the basis of having any other Axis I disorder but this exclusion criterion
was present in over a quarter (27%) of the antidepressant trials
(p=0.08). Table 2 shows the frequency with which specific disorders
were used as exclusion criteria, either explicitly stated or as part of a
broader exclusion criterion (e.g., exclusion for any anxiety disorder). As
can be seen in the table, some of the differences in the frequency with
which studies excluded particular diagnoses were quite large. For ex-
ample, around half of antidepressant studies excluded subjects on the
basis of having posttraumatic stress disorder (PTSD; 44%) or obsessive-
compulsive disorder (OCD; 47%) but having these disorders was rarely
an exclusion criterion in psychotherapy studies (PTSD: 6%,
p < 0.0001; OCD: 13%, p < 0.0001). Statistical trends in the data
suggested that the psychotherapy studies were less likely to exclude
based on generalized anxiety, social anxiety, and panic disorder.
Psychotherapy trials were less likely to use as exclusion criterion a
minimum score on a symptom severity measure (81% vs. 100%,
p < 0.001). Furthermore, we observed that even when they used
symptom severity to exclude participants, psychotherapy studies were
still more inclusive of individuals lower on symptom severity. This
observation could be explored quantitatively in the subset of studies
that used a common exclusion measure, namely the 17-item version of
the Hamilton Rating Scale for depression, which was used in 9 psy-
chotherapy studies (56%) and 105 antidepressants studies (62%). The
lowest allowable score on the HRSD-17 for entry into a medication trial
was a 14, and the next-most low score was a 15. By way of contrast, the
lowest allowable score on the HRSD-17 for entry in a psychotherapy
study was a was a 7, and the next lowest score was a 10. Most medi-
cation (86%) studies that used the HRSD-17 required that participants
have a score of at least 16, which is typically interpreted to reflect
depressive symptoms of moderate (Kriston & Wolff, 2011) or mild-to-
moderate (Zimmerman et al., 2013) intensity. By contrast, a severity
exclusion in the same range was only found in 2 psychotherapy studies
(13%; p < 0.001), one that required a score of 17 on the HRSD-17 and
another that required a score of 20. Six psychotherapy studies used the
Beck Depression Inventory (Beck et al., 1996) to exclude on the basis of
symptom severity. The range of scores used in these studies was from 10
to 20 and 3 of the 6 studies used scores below 19, which are tradi-
tionally interpreted to represent mild depressive symptoms. Taken to-
gether, these data would appear to suggest that even when psy-
chotherapy studies used severity exclusions, they allow for the inclusion
of individuals with milder depression while medication trials require
symptom scores that indicate moderate or severe depression. Although
psychotherapy studies were overall less exclusive, and specifically ap-
pear more inclusive of milder forms of depression they were more likely
to use a maximum score on measures of symptom severity as an ex-
clusion criterion (8% vs. 38%, p=0.0029).
4. Discussion
To our knowledge, this is the first comparison of the specific in-
clusion and exclusion criteria used in randomized controlled trials of
psychotherapies and antidepressants for major depression. On the basis
of previous research (Franco et al., 2016; Hoertel et al., 2014, 2015), we
hypothesized that research on psychotherapy for adult depression
would be more inclusive than research on antidepressants. Most psy-
chotherapy and antidepressant studies excluded patients who were low
on symptoms severity, had substance use pathologies, imminent sui-
cidality, or psychotic disorders/symptoms. However, as hypothesized,
psychotherapy studies were more inclusive. Specifically, they were less
likely to exclude patients on the basis of having brief episodes, lower
symptom severity, and specific diagnoses such as OCD, PTSD, and bu-
limia. Even when they excluded on the basis of symptom severity, the
Table 1
Frequency of commonly-used psychiatric inclusion and exclusion criteria in randomized
controlled trials of antidepressants (n= 170) or psychotherapy (n= 16).
n % n % p
Severity scale score below cutoff 170 100% 13 81% 0.00
Psychotic disorder/current psychotic features 143 84% 14 88% 1.00
Substance abuse/dependence 137 81% 12 75% 0.53
Significant suicidal ideation 128 75% 9 56% 0.13
Episode duration too short 81 48% 2 13% 0.00
Any Axis II disorder 60 35% 3 19% 0.27
Any Axis I disorder 46 27% 1 6% 0.08
History of suicide attempt(s) 35 21% 2 13% 0.74
Episode duration too long 34 20% 2 13% 0.74
Significant homicidal ideation/violence risk 28 16% 0 0% 0.14
Severity scale score above cutoff 14 8% 6 38% 0.00
Note. a p value from χ2 statistic or by Fisher exact test if the expected value in any cell of a
2× 2 table was less than 5.
Table 2
Frequency of exclusion of specific Axis I and Axis II disorders in randomized controlled
trials of antidepressants (n=170) or psychotherapy (n= 16).
n % n % p
Drug abuse 130 76% 13 81% 1.000
Alcohol abuse 129 76% 13 81% 0.766
Alcohol dependence 109 64% 13 81% 0.270
Drug dependence 107 63% 13 81% 0.178
Obsessive-compulsive disorder 80 47% 2 13% 0.008
Posttraumatic stress disorder 75 44% 1 6% 0.003
Borderline personality disorder 70 41% 5 31% 0.596
Antisocial personality disorder 68 40% 5 31% 0.598
Bulimia nervosa 66 39% 3 19% 0.012
Anorexia nervosa 66 39% 5 31% 0.603
Panic disorder 65 38% 2 13% 0.055
Schizotypal personality disorder 63 37% 5 31% 0.789
Generalized anxiety disorder 50 29% 1 6% 0.074
Social anxiety disorder 48 28% 1 6% 0.074
Dysthymic disorder 46 27% 2 13% 0.175
Specific phobia 45 26% 1 6% 0.125
Note. a p value from χ2 statistic or by Fisher exact test if the expected value in any cell of a
2×2 table was less than 5.
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psychotherapy studies tended to be more inclusive of individuals with
milder symptoms. Thus, relative to the research base on psychotherapy,
studies of antidepressants appear to select patients with a more severe
and chronic, albeit purely depressive, presentation.
Before interpreting the current findings, it is important to note
significant limitations of our report. We focused solely on RCTs that
included a control condition. Placebos are used almost universally as
controls in antidepressant treatment RCTs (Huhn et al., 2014). By
contrast, the number of placebo-controlled psychotherapy studies was
small (n= 4) and other comparison groups, most often TAU or a
waiting list, tended to be used. It may not be appropriate to make
comparisons of these two treatment literatures given that the controls
differ. Overall, the number of RCTs of psychotherapy was small. Ad-
ditionally, we focused exclusively on published trials. This introduces
the possibility that treatment differences in publication bias somehow
relate to differences in the exclusion criteria the trial used. Publication
bias relating to efficacy has been documented for both psychotherapy
(Driessen et al., 2015) and antidepressant treatments trials (Turner
et al., 2008), though it appears to occur with comparable frequency in
psychotherapy (24% non-publication rate) and antidepressant trials
(31%). Finally, it is worthwhile noting that we focused on the inclusion
and exclusion criteria that were listed in the published report. It is
possible that antidepressant studies do not use more exclusion criteria
than psychotherapy studies but that researchers conducting pharma-
cological studies are simply more rigorous in their reporting.
A substantial proportion of studies excluded patients due to psy-
chotic symptoms, substance abuse/dependence, and suicidality and the
rates did not appear to differ between antidepressant and psy-
chotherapy trials. On the one hand, it might seem appropriate to ex-
clude patients with these clinical features from treatment studies in that
they might require a different level of care (e.g., hospitalization) or a
treatment that is not being studied (e.g., antipsychotics). On the other
hand, the exclusion of these patients from the treatment literature re-
duces the external validity of the findings from clinical research in ways
that have been well -articulated (Morrison et al., 2003; Zimmerman
et al., 2002). Excluding these patients from efficacy research represents
somewhat of a “Catch-22.” The patients are excluded from research
because they are deemed inappropriate, and there is no research
speaking to the appropriateness of delivering these treatments to these
patients, though they may receive them in the community. There is
limited evidence that patients who report psychotic symptoms, pro-
blematic substance use, and suicidality experience poorer outcomes in
treatment (Kessler et al., 2016). For example, van der Lem et al. (2012)
reported that current or past substance use was unrelated to outcomes
in a naturalistic sample of depressed patients. However, it would not be
unreasonable to assume that outcomes for these patients may vary
within medication classes or types of psychotherapy. The fact that these
patients are not well represented in the treatment literature thus pre-
cludes the identification of specific treatments that may be potentially
more efficacious for them or, conversely, treatments that may not help
them at all. The fact that these specific exclusion criteria – psychotic
symptoms, substance misuse, and suicidality – have been so frequently
applied in treatment trials underscores the need for effectiveness re-
search using fewer exclusionary criteria. As well, more attention needs
to be paid to developing and testing treatments that target more than
one form of psychopathology (e.g., McHugh et al., 2017).
Although, as hypothesized, the overall trend we found was that
psychotherapy studies were more inclusive of patients, they were more
likely to exclude patients on the basis of having more severe symptoms.
This might reflect the enforcement of treatment guidelines (American
Psychiatric Association, 2010; Anderson et al., 2008), which were based
on a large study suggesting that pharmacotherapy was more effective
than CBT for cases of severe depression (Elkin et al., 1995). Individual
trials (DeRubeis et al., 2005), study level meta-analyses (Driessen et al.,
2010), and individual patient meta-analyses (Weitz et al., 2015) sub-
sequent to this study have failed to replicate this finding and suggest
that CBT, and possibly other therapies, can be as effective as medica-
tions for more severe depression. Thus, until more evidence emerges
that patients with more severe depression have limited success with
psychotherapy, or specific kinds of psychotherapy, these individuals
should not be excluded from psychotherapy treatment trials. Indeed,
these individuals need to be included in treatment trials if any evidence
is to emerge suggesting that psychotherapy, or specific kinds of psy-
chotherapy, are less effective than medications for patients with more
severe symptoms. Existing data suggest that the combination of medi-
cations and psychotherapy are superior to either as a monotherapy
(Cuijpers et al., 2010, 2009) so future research should also explore the
entry criteria employed in these studies.
One of the most commonly-used criteria was the exclusion of pa-
tients with milder symptoms. Although, this was somewhat less likely
to happen in psychotherapy studies, most (81%) studies used a
minimum severity criterion to exclude patients. Antidepressant studies
most often utilized a version of the HRSD to determine study inclusion
whereas psychotherapy studies used the HRSD, the BDI, and various
other scales. Thus, it may not be appropriate to consider the severity
exclusions on equal footing. However, we found some evidence to
suggest that even when psychotherapy studies used the HRSD, the cut-
off scores tended to be relatively low, thus allowing for the inclusion of
patients with mild major depressive disorder. As discussed previously,
the targeting of psychotherapy trials to patients with mild to moderate
MDD may reflect the belief that psychotherapy is only effective for this
patient group (Elkin et al., 1995). The targeting of medication studies to
patients with more severe symptoms may reflect a belief that medica-
tions are more suitable for cases of more severe depression. Indeed,
meta-analyses and analyses of pooled study data casts doubt on the
efficacy of antidepressants relative to placebos for less severe depres-
sion (Barbui et al., 2011; Fournier et al., 2010; Khan et al., 2002; Kirsch
et al., 2008), though these findings have not been universally observed
(Rabinowitz et al., 2016), and may not be applicable to more chronic
depression or dysthymia (Cuijpers et al., 2008a). It is unclear whether
severity is also a moderator of response in psychotherapy vs. control
conditions (Driessen et al., 2010; Furukawa et al., 2017). However, the
fact that the range of severity is not well-represented in the existing
treatment literature is still a cause for concern, limiting even the studies
that attempt to explore whether severity is a moderator of treatment
outcomes. Nationally representative data suggest that a substantial
proportion of individuals who receive prescriptions for antidepressant
medications do not meet the full criteria for an anxiety or mood dis-
order, much less a severe one (Mojtabai and Olfson, 2008; Pagura et al.,
2011; Takayanagi et al., 2014) and it is probable that the same is true of
patients undergoing psychotherapy. Thus, there is a clear disconnect
between the patient populations studied in these trials and the patients
who typically receive such treatments, and little in the way of empirical
data suggesting how to best treatment milder forms of depressions
(Middleton, 2005).
Researchers often perceive a trade-off between internal and external
validity (Kazdin, 2016) and associate restrictive exclusion/inclusion
criteria with lower external validity and higher internal validity (Blanco
et al., 2008). Most of the studies we analyzed were designed to have
high internal validity as they were treatment efficacy trials conducted
in academic or academic-medical settings. In these efficacy studies, it
may be sensible to employ specific trial entry criteria to maximize de-
tecting treatment effects (i.e., increasing internal validity thereby
lowering external validity). The expectation is that subsequent “effec-
tiveness” studies evaluate the generalizability of the findings by re-
laxing inclusion and exclusion criteria, thus increasing external validity.
However, diminished external validity does not guarantee increased
internal validity. For example, Hoertel et al. (2013) have argued that
some exclusion criteria may lead both to lowered external validity as
well as internal validity because the sample under study may under-
estimate treatment effects. While some of the commonly-used inclu-
sion/exclusion criteria (e.g., mild severity) may increase the likelihood
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of finding treatment effects (Fournier et al., 2011), other criteria (e.g.,
alcohol use disorder) may not (van der Lem et al., 2012). It is also worth
noting that concerns have been raised about the transportability of
antidepressant (Rutherford et al., 2013) and psychotherapy (Weisz and
Gray, 2008) treatments to “real-world” settings. Thus, the inclusion and
exclusion criteria are not the only factors bearing on the general-
izability of findings from treatment studies.
5. Summary and conclusions
As hypothesized, when differences between the psychotherapy and
antidepressant studies emerged, psychotherapy studies seemed less
likely to use exclusion criteria. Specifically, these studies were less
likely to employ low symptom severity, brief episode duration, and co-
morbid Axis I pathology as reasons for exclusion. These findings par-
allel the treatment literature on borderline personality (Hoertel et al.,
2015), social anxiety (Hoertel et al., 2014), and post-traumatic stress
disorder (Franco et al., 2016) which also suggests that psychotherapy
studies might be more representative than pharmacotherapy studies.
The findings, however, are somewhat disheartening because most
outpatients who are depressed are treated with antidepressant medi-
cations instead of psychotherapy (Olfson and Marcus, 2010). Thus,
more comparative effectiveness research with less stringent inclusion
criteria is needed.
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